Incidence of childhood cancer in Canada during the COVID-19 pandemic.
Journal
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
ISSN: 1488-2329
Titre abrégé: CMAJ
Pays: Canada
ID NLM: 9711805
Informations de publication
Date de publication:
29 11 2021
29 11 2021
Historique:
accepted:
04
10
2021
entrez:
30
11
2021
pubmed:
1
12
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic has had a major impact on access to health care resources. Our objective was to estimate the impact of the COVID-19 pandemic on the incidence of childhood cancer in Canada. We also aimed to compare the proportion of patients who enrolled in clinical trials at diagnosis, presented with metastatic disease or had an early death during the first 9 months of the COVID-19 pandemic compared with previous years. We conducted an observational study that included children younger than 15 years with a new diagnosis of cancer between March 2016 and November 2020 at 1 of 17 Canadian pediatric oncology centres. Our primary outcome was the monthly age-standardized incidence rates (ASIRs) of cancers. We evaluated level and trend changes using interventional autoregressive integrated moving average models. Secondary outcomes were the proportion of patients who were enrolled in a clinical trial, who had metastatic or advanced disease and who died within 30 days. We compared the baseline and pandemic periods using rate ratios (RRs) and 95% confidence intervals (CIs). Age-standardized incidence rates during COVID-19 quarters were 157.7, 164.6, and 148.0 per million, respectively, whereas quarterly baseline ASIRs ranged between 150.3 and 175.1 per million (incidence RR 0.93 [95% CI 0.78 to 1.12] to incidence RR 1.04 [95% CI 0.87 to 1.24]). We found no statistically significant level or slope changes between the projected and observed ASIRs for all new cancers (parameter estimate [β], level 4.98, 95% CI -15.1 to 25.04, We did not observe a statistically significant change in the incidence of childhood cancer, or in the proportion of children enrolling in a clinical trial, presenting with metastatic disease or who died early during the first 9 months of the COVID-19 pandemic, which suggests that access to health care in pediatric oncology was not reduced substantially in Canada.
Sections du résumé
BACKGROUND
The COVID-19 pandemic has had a major impact on access to health care resources. Our objective was to estimate the impact of the COVID-19 pandemic on the incidence of childhood cancer in Canada. We also aimed to compare the proportion of patients who enrolled in clinical trials at diagnosis, presented with metastatic disease or had an early death during the first 9 months of the COVID-19 pandemic compared with previous years.
METHODS
We conducted an observational study that included children younger than 15 years with a new diagnosis of cancer between March 2016 and November 2020 at 1 of 17 Canadian pediatric oncology centres. Our primary outcome was the monthly age-standardized incidence rates (ASIRs) of cancers. We evaluated level and trend changes using interventional autoregressive integrated moving average models. Secondary outcomes were the proportion of patients who were enrolled in a clinical trial, who had metastatic or advanced disease and who died within 30 days. We compared the baseline and pandemic periods using rate ratios (RRs) and 95% confidence intervals (CIs).
RESULTS
Age-standardized incidence rates during COVID-19 quarters were 157.7, 164.6, and 148.0 per million, respectively, whereas quarterly baseline ASIRs ranged between 150.3 and 175.1 per million (incidence RR 0.93 [95% CI 0.78 to 1.12] to incidence RR 1.04 [95% CI 0.87 to 1.24]). We found no statistically significant level or slope changes between the projected and observed ASIRs for all new cancers (parameter estimate [β], level 4.98, 95% CI -15.1 to 25.04,
INTERPRETATION
We did not observe a statistically significant change in the incidence of childhood cancer, or in the proportion of children enrolling in a clinical trial, presenting with metastatic disease or who died early during the first 9 months of the COVID-19 pandemic, which suggests that access to health care in pediatric oncology was not reduced substantially in Canada.
Identifiants
pubmed: 34844937
pii: 193/47/E1798
doi: 10.1503/cmaj.210659
pmc: PMC8654886
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
E1798-E1806Informations de copyright
© 2021 CMA Joule Inc. or its licensors.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Biometrics. 2004 Dec;60(4):1005-14
pubmed: 15606421
J Clin Oncol. 1996 Jan;14(1):18-24
pubmed: 8558195
Neuro Oncol. 2020 Dec 18;22(12):1884-1886
pubmed: 32623465
Int J Infect Dis. 2020 Jul;96:506-508
pubmed: 32425633
Pediatr Blood Cancer. 2021 Feb;68(2):e28615
pubmed: 32725878
JAMA Netw Open. 2020 Aug 3;3(8):e2017267
pubmed: 32749465
Health Promot Chronic Dis Prev Can. 2015 Jun;35(4):73-6
pubmed: 26083522
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
Lancet Oncol. 2012 Oct;13(10):e445-59
pubmed: 23026830
JCO Clin Cancer Inform. 2020 Jul;4:657-665
pubmed: 32716647
JCO Oncol Pract. 2020 Jul;16(7):417-421
pubmed: 32396491
BMC Med Res Methodol. 2021 Mar 22;21(1):58
pubmed: 33752604
Pediatr Blood Cancer. 2020 Sep;67(9):e28427
pubmed: 32588960
JAMA Netw Open. 2021 Aug 2;4(8):e2118441
pubmed: 34338794
Pediatr Blood Cancer. 2020 Oct;67(10):e28640
pubmed: 32761998
Eur J Cancer. 2020 Dec;141:82-91
pubmed: 33129040
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):109-113
pubmed: 33507893
Lancet Child Adolesc Health. 2020 May;4(5):e10-e11
pubmed: 32278365
BMJ Open. 2020 Nov 17;10(11):e043828
pubmed: 33203640
Cancer. 2005 Apr 1;103(7):1457-67
pubmed: 15712273
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
CMAJ. 2020 Apr 14;192(15):E420
pubmed: 32392510
Ann Med Surg (Lond). 2020 Dec;60:675-679
pubmed: 33282280
JCO Clin Cancer Inform. 2020 Nov;4:1059-1071
pubmed: 33253013
Arch Dis Child. 2021 Feb;106(2):e8
pubmed: 32586927
Clin Transl Oncol. 2021 Jan;23(1):183-189
pubmed: 32472454
Pediatr Res. 2021 Apr;89(5):1101-1108
pubmed: 32679582
Int J Cancer. 2003 May 20;105(1):88-91
pubmed: 12672035
J Natl Cancer Inst. 2021 Nov 2;113(11):1453-1459
pubmed: 32959883
Paediatr Child Health. 2006 Mar;11(3):148-50
pubmed: 19030270
JAMA Netw Open. 2020 Jun 1;3(6):e2010651
pubmed: 32478845
BMC Cancer. 2017 Jun 5;17(1):402
pubmed: 28583094